Notice: This company has been marked as potentially delisted and may not be actively trading. Immune Pharmaceuticals (IMNP) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period AC Immune stock jumps 20% on data for Parkinson's disease drugNovember 14, 2024 | msn.comBest Immunity Supplements for 2024August 31, 2024 | cnet.comDrug Helps Reprogram Macrophage Immune Cells, Suppress Prostate and Bladder Tumor GrowthMay 22, 2024 | msn.comAC Immune and Takeda Sign $2.2 Billion Alzheimer’s Drug DealMay 13, 2024 | bloomberg.comIncyte to acquire immune-focused drug developer EscientApril 23, 2024 | msn.comVertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street Says.April 11, 2024 | msn.comThese Stocks Are Moving the Most Today: Alpine Immune, Regeneron, Costco, Constellation Brands, CarMax, and MoreApril 11, 2024 | msn.comThese Stocks Are Moving the Most Today: Alpine Immune, Vertex, Regeneron, Costco, Constellation Brands, CarMax, and MoreApril 11, 2024 | msn.comOSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of ImmunologyApril 2, 2024 | markets.businessinsider.comAC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b TrialDecember 15, 2023 | tmcnet.comAC Immune Advances Anti-pTau Active Immunotherapy For Alzheimer's Disease Into Phase 2b TrialDecember 15, 2023 | markets.businessinsider.comImmune Health Supplements Market US$ 63,457.4 Million Valuation in 2033, Experiencing an Impressive CAGR of 10.4% | Future Market Insights Inc.September 14, 2023 | benzinga.comOrgan Transplant Rejection Medication Market to Surpass USD 7.0 Billion by 2031, Propelled by Remarkable CAGR of 3.9% | Transparency Market ResearchJune 8, 2023 | es-us.finanzas.yahoo.comTheralase Technologies Inc.: Theralase Announces Appointment of New Independent DirectorJune 6, 2023 | finanznachrichten.deTheralase(R) Announces Appointment of New Independent DirectorJune 6, 2023 | finance.yahoo.comSeveral Down syndrome features may be linked to a hyperactive antiviral immune response – new researchJune 5, 2023 | msn.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public OfferingJune 2, 2023 | finanznachrichten.deKiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public OfferingJune 2, 2023 | finance.yahoo.comMedexus Pharmaceuticals Inc.: Medexus to Participate in the LD Micro Invitational XIIIJune 1, 2023 | finanznachrichten.deBristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?June 1, 2023 | finance.yahoo.comHookipa Pharma (HOOK) Gets a Buy from JMP SecuritiesJune 1, 2023 | markets.businessinsider.comPhanes Therapeutics announces the appointment of Rita Laeufle, MD, PhD, as Chief Medical OfficerMay 30, 2023 | markets.businessinsider.comX4 Pharmaceuticals (XFOR) Gets a Buy from Stifel NicolausMay 29, 2023 | markets.businessinsider.comHC Wainwright & Co. Reiterates Eledon Pharmaceuticals (ELDN) Buy RecommendationMay 27, 2023 | nasdaq.comCalciMedica Expands Executive Team with New AppointmentsMay 23, 2023 | finance.yahoo.comBiotech Entrepreneur and Venture Capitalist Dinesh Patel Discusses Therapeutics and Medical Devices with CancerVAX CEO Ryan DaviesMay 17, 2023 | technews.tmcnet.comMyocardial Infarction Drugs Market Size and Projection from 2023 to 2030May 17, 2023 | marketwatch.comB.Riley Financial Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)May 17, 2023 | markets.businessinsider.comCAR T-Cell Therapy Market to be Worth $51.6 Billion by 2030 - Exclusive Report by Meticulous Research®May 16, 2023 | benzinga.comLiver Failure Therapeutics Market 2023-2031: Analyzing Growth Opportunities and ChallengesMay 12, 2023 | marketwatch.comLingering nerve symptoms from Lyme disease may be tied to immune responseMay 12, 2023 | reuters.com8-K: INOVIO PHARMACEUTICALS, INC.May 11, 2023 | marketwatch.comTRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | finanznachrichten.deModerna's Revolutionary Cancer Vaccine Sets Investors AbuzzMay 11, 2023 | forbes.com8-K: Corbus Pharmaceuticals Holdings, Inc.May 9, 2023 | marketwatch.com10-Q: KIORA PHARMACEUTICALS INCMay 9, 2023 | marketwatch.comCorbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 9, 2023 | finanznachrichten.deMizuho Securities Sticks to Their Hold Rating for Corvus Pharmaceuticals (CRVS)May 8, 2023 | markets.businessinsider.comEQRx lays off more than half its staff, pivots againMay 8, 2023 | bizjournals.comCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial ResultsMay 8, 2023 | finance.yahoo.comXencor Reports First Quarter 2023 Financial ResultsMay 8, 2023 | businesswire.comNeedham Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To KnowMay 5, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on X4 Pharmaceuticals (XFOR)May 5, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for BioCryst (BCRX)May 4, 2023 | markets.businessinsider.comFDA Approves First-Ever RSV Vaccine for Adults 60 and OlderMay 3, 2023 | msn.comRigel Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 2, 2023 | markets.businessinsider.comLatest Developments in the Amyotrophic Lateral Sclerosis Pipeline | Major Companies – Biogen, AbbVie, and OthersMay 2, 2023 | marketwatch.comDelveInsight Evaluates a Robust Antibody-drug Conjugates in Oncology Clinical Trial Pipeline as 30+ Influential Pharma Players to Set Foot in the 7MMMay 1, 2023 | benzinga.com2023-2030 Drug Induced Immune Hemolytic Anemia Market Size (Growth and Outlook) includes Company Information | with [102 Pages]April 27, 2023 | marketwatch.comLatest Trends and Strategies for Immune Thrombocytopenia Drugs Market During 2023-2031April 27, 2023 | marketwatch.com Get Immune Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNP and its competitors with MarketBeat's FREE daily newsletter. Email Address I hate to say I told you so (Ad)Last month, I openly declared that a Trump Presidency was going to kick off Tesla’s New Bullish Cycle Folks who listened and bought in when I said to are currently crushing it. As a matter of fact, all the trades we’ve opened ever since I made that public declaration have ALL been winners. And it’s simply because this Tesla indicator just flipped green on the stock… Follow this link right away. IMNP Media Mentions By Week IMNP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMNP News Sentiment▼0.000.49▲Average Medical News Sentiment IMNP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMNP Articles This Week▼00▲IMNP Articles Average Week Get Immune Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LTRN News ACST News PMN News OCUP News KALA News RNXT News CTXR News BIVI News BCTX News DARE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMNP) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immune Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
